NCT02622334View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 29, 2015

Primary Completion Date

July 28, 2016

Study Completion Date

July 28, 2016

Conditions
Glaucoma
Interventions
DRUG

Latanoprost

Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.

DRUG

Placebo

Matching placebo formulation will be administered in Part A.

DRUG

RO5093151

RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.

Trial Locations (7)

10003

New York Eye and Ear Infirmary of Mt. Sinai; New York Glaucoma Research Institute, New York

26506

West Virginia University Eye Institute, Morgantown

27262

Cornerstone Eye Care, Div of Cornerstone Health Care, High Point

30260

Eye Care Centers Management, Inc. (Clayton Eye Center), Morrow

80045

Rocky Mountain Lions Eye Inst, Aurora

90701

Sall Research Medical Center, Artesia

168751

Singapore National Eye Centre; Glaucoma Department, Singapore

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02622334 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). | Biotech Hunter | Biotech Hunter